Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large Cap Fund median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 100 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Tata Large Cap Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹105.52 |
| 12 Apr 2015 | ₹158.44 |
| 31 May 2016 | ₹155.05 |
| 19 Jul 2017 | ₹193.37 |
| 07 Sep 2018 | ₹216.23 |
| 27 Oct 2019 | ₹221.98 |
| 15 Dec 2020 | ₹242.89 |
| 03 Feb 2022 | ₹342.96 |
| 25 Mar 2023 | ₹330.72 |
| 12 May 2024 | ₹466.51 |
| 01 Jul 2025 | ₹533.34 |
| 20 Aug 2026 | ₹544.84 |
| Metric | Tata · Direct NAV ₹595.76 Very High risk ★★★☆☆ | Category median Large Cap Fund · 35 funds |
|---|---|---|
| +3.61% | +0.75% | |
| +12.39% | +12.33% | |
| +11.56% | +11.21% | |
| +12.51% | +12.51% | |
| +13.25% | +13.22% | |
| +10.72% | — | |
| +14.04% | +14.61% | |
| +13.78% | +13.78% | |
| +13.82% | +13.95% | |
| Risk | ||
| 13.81% | 13.24% | |
| 0.43 | 0.43 | |
| 0.58 | 0.58 | |
| -37.57% | -35.14% | |
| Nifty 100 | — | |
| +2.33% | +2.33% | |
| 1.00 | 0.96 | |
| 105.1% | 103.3% | |
| 92.1% | 91.0% | |
| 1.23% | 1.07% | |
| ₹2,471Cr | ₹2,004Cr | |
| 0.50% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 23% | 50% | |
| Hasmukh Vishariya | — | |
| 02 Jan 2013 | — | |
| 44 | — | |
| 43.9% | — | |
| 2.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.